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DMD #16485
DMD #16485 (Introduction) The human N-acetyltransferase 1 (NAT1) and 2 (NAT2) genes encode Nacetyltransferases enzymes important in the biotransformation of xenobiotics, including pharmaceuticals and environmental carcinogens. Polymorphisms within and near the single open reading frame exon of NAT1 define more than 25 distinct haplotypes (Hein et al., 2000) .
Associations of NAT1 polymorphisms with susceptibility to various cancers (Hein et al., 2000; Boukouvala and Fakis, 2005) and birth defects (Carmichael et al., 2006; Jensen et al., 2006) have been described, however the effects of the common NAT1 polymorphisms on enzyme activity have not been well established and their reported associations with cancer or birth defects are inconsistent. The apparent conflicts in epidemiological studies may be due, in part, to incomplete understanding of the effects of uncharacterized genetic and environmental influences on NAT1 transcription regulation.
Numerous studies have documented interindividual differences in NAT1 protein or enzyme activity in diverse human tissues including erythrocytes (Bruhn et al., 1999) , intestine (Hickman et al., 1998) , colon (Ilett et al., 1994) , skin (Kawakubo et al., 2000) , breast (Williams et al., 2001) , placenta and prostate (Al-Buheissi et al., 2006) with no known genetic basis. Although the NAT1 alleles NAT1*14B, *15, *17,*19 and *22 are known to encode proteins with low enzyme activity (Fretland et al., 2001) , these forms are rare in humans and variable activity has also been reported for individuals homozygous or heterozygous for the most frequent NAT1*4 and *10 alleles. Some of the observed variability is likely due to posttranslational effects caused by intracellular redox or metabolic status (Butcher et al., 2000; Butcher et al., 2004; Rodrigues-Lima and Dupret, 2004) , but the influence of NAT1 transcriptional regulation has not yet been determined.
Two alternative NAT1 promoters, recently renamed NATa and NATb (Minchin et al., 2007) , are respectively located 51.5 kb and 11.8 kb upstream of the single translated exon.
Transcription of NAT1 occurs in a wide variety of tissues and cell lines and most mRNAs are
This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on as DOI: 10.1124 at ASPET Journals on January 13, 2018 dmd.aspetjournals.org Downloaded from DMD #16485 5 initiated at NATb (Husain et al., 2004; Boukouvala and Fakis, 2005; Butcher et al., 2005) . The alternative promoter, NATa, is most highly expressed in a few tissues, including kidney, liver, lung and trachea (Barker et al., 2006) . The pattern of placental NAT1 expression during human development and the temporal and spatial expression of mouse Nat2, the likely ortholog of human NAT1, during cardiogenesis and at neural closure (Wakefield et al., 2005) are probable examples of transcriptional regulation. An androgen analog was recently shown to increase NAT1 mRNA by stimulation of transcription initiation at NATb in two prostate cancer cell lines (Butcher et al., 2007) . The high expression of NAT1 in many estrogen receptor positive breast tumors is also apparently due to higher mRNA production (Perou et al., 2000; Adam et al., 2003; Sorlie et al., 2003; Tozlu et al., 2006) . Further understanding of the increased NAT1 expression in breast tumors is of interest because of the role of NAT1 in biotransforming environmental carcinogens and the observed association of higher NAT1 expression with better patient survival (Bieche et al., 2004; Dolled-Filhart et al., 2006) . Further characterization of the NATb promoter is presented here, including quantitation of expression in diverse human tissues and identification of specific functional elements within the minimal promoter sequence.
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Materials and Methods
Human RNA samples. Two panels of pooled, purified, tissue-specific, human total RNAs from Ambion (Ambion Inc., Austin, TX) and BD (BD Biosciences Clontech, Palo Alto, CA) and RNAs from the HepG2, HT-29, MCF-7, SW480, Caco-2, HEK293 and A549 human cell lines were as described previously (Barker et al., 2006; Husain et al., 2007) . A sample of breast RNA, from one female and a liver RNA sample from one male were also obtained from Ambion.
Additional RNAs representing adrenal gland, bladder and liver were obtained from BD.
Quantitative real-time RT-PCR. TaqMan analysis was performed using the ABI 7700 sequence detection system (Applied Biosystems, Foster City, CA). The 20 µl PCR reactions were 1X TaqMan Universal Master Mix, with 300 nM forward and reverse primers and 100 nM probe. The sequence of the NATb-specific forward primer (Table 1) is within the first exon of the major NAT1 mRNA. The sequences of the reverse primer and the probe (Table 1) are within the NAT1 open reading frame exon and the 79 base 5'-untranslated exon respectively. For PCR, initial incubations at 50°C for 2 min and 94°C for 10 min were followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 min. Quantitation of the endogenous control 18S rRNA was performed using TaqMan Ribosomal RNA Control Reagents for 18S rRNA (Applied Biosystems). Four µl of diluted cDNA, equivalent to 40 ng of the initial RNA template, was used in each PCR. Two independent RT reactions were prepared for each RNA and TaqMan measurements were carried out in duplicate for each cDNA product, for a total of four readings.
Controls and calculations of relative mRNA quantity were as previously described (Barker et al., 2006) . For each RT set, the relative measures obtained from the two real-time runs were averaged and normalized with respect to the average of all samples in the same RT group.
Construction of pGL3-Basic promoter clones and artificial mutant derivatives. For construction of NATb promoter segment clones, DNA from the BAC CTD2547-L16 was used as template for PCR with the high fidelity Phusion polymerase (New England Biolabs, Ipswich, MA) using primers with artificial 5' HindIII sites (Table 1) , followed by cloning into the HindIII This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on June 25, 2007 as DOI: 10.1124 at ASPET Journals on January 13, 2018 dmd.aspetjournals.org Downloaded from DMD #16485 site of pGL3-Basic (Promega, Madison, WI). Artificial mutant derivatives of the 318 bp promoter fragment were constructed as described (Ho et al., 1989) or with the modification that restriction enzyme digestion and ligation with T4 DNA ligase was used to accomplish fusion of the primary PCR products. Template DNAs for site-directed mutagenesis were either the genomic BAC clone CTD2547L16, the 318 promoter plasmid or, for the construction of the double mutant, a derivative of the 318 promoter plasmid carrying a Dup1-R7 mutation. Primers with mutant sequences and outer nested primers appropriate to each template were used ( Table   1 ).
The final inner nested PCR was carried out with primers NATb 318H3 and NAT1TSSZeroRevH3 (Table 1) , and the resulting products were cloned into the HindIII site of pGL3-Basic. The presence of mutations was monitored by restriction enzyme digestion and verified by sequencing of plasmid DNAs with the ABI Big Dye Termination Reagents and the 310 Genetic Analyzer (Applied Biosystems).
Selection and retrieval of genomic promoter sequences for cross-species comparisons.
Genomic segments containing the human NATb promoter sequence (Husain et al., 2004 ) and the corresponding promoter sequences from other genes and organisms (Boukouvala and Fakis, 2005) were retrieved at the Genome Browser Gateway (Kent et al., 2002) (http://genome.ucsc.edu/) and aligned using ClustalW (http://www.ebi.ac.uk/services/). The human NAT2 promoter region was as previously defined (Ebisawa and Deguchi, 1991; Husain et al., 2007) . A promoter for mouse Nat2 has been described (Boukouvala et al., 2003) and the surrounding genomic sequences were retrieved following alignment of the 5' ends of NCBI (http://www.ncbi.nlm.nih.gov/) nucleotide database cDNAs CA494799, CN663986 and BF164333 with the mouse genome using BLAT (Kent, 2002) as implemented at the Genome Browser Gateway. A candidate promoter region serving for both rat Nat1 and Nat2 was inferred from the structures of previously isolated cDNA clones (Ebisawa et al., 1995) . Rat genomic sequence corresponding to the 5' portion of these cDNAs was obtained at the Genome Browser
Gateway by BLAT alignment of NCBI cDNAs U01343 for rat Nat1 and U01347 and U01348 for Nat1 cDNA has been reported, expression of the Nat1 isoenzyme and Nat1 mRNA in mouse tissues is well documented (Hein et al., 1988; McQueen and Chau, 2003; Loehle et al., 2006) . A candidate promoter region for mouse Nat1 was detected by alignment of the 1200 bp rat promoter segment within a 12.5 kb mouse genomic segment upstream of the mouse Nat1 coding exon.
This alignment identified a mouse DNA segment of 1176 bp that is 9.8 kb upstream of the mouse Nat1 coding exon and is 82% identical to the rat promoter segment.
Transcription factor database analysis. TFSEARCH however. In series A, for instance, the small intestine sample had more than 3-fold higher mRNA than the prostate sample, but in series B, the prostate level was 4 fold that of small intestine. Also in series A, mRNA in trachea was 5.5 fold higher than bladder, but in series B, the bladder level Effects of the mutations on relative promoter activity levels were similar with both cell lines. The
Con1-R7 mutation, ttcccag>gggatcc, at the overlap between the 19 nucleotide conserved region and the 5' portion of the 16 nucleotide palindrome, caused a 3 to 4-fold reduction in promoter activity. The Pal 11/16 mutation, gggcccctggg>tttaaaaattt, which alters the remaining 3' portion of the palindrome, reduced promoter activity by 2-to 3-fold, but the mutation Con1-L9, ctgcaacta>ggatccagc, which alters only the 5' portion of the 19 nucleotide conserved region had a lesser effect on promoter strength. It is notable that the NATb 178 construct which is completely deleted for the sequences corresponding to both the 19 nucleotide conserved region and the palindrome ( Figure 5 ) did not show less promoter activity than any of the individual mutations, suggesting that the absence of all of these sites did not have a compound effect.
A partial deletion combined with two nucleotide changes in the putative Sp1 site, Sp1 del4+GC->AT (cggggc>at), reduced promoter activity nearly 10-fold in both MCF-7 and HepG2.
A second mutation, Sp1 G3G4->AT, changing only the two most conserved positions of the consensus Sp1 sequence, as defined by TRANSFAC M00196, also resulted in a large reduction This article has not been copyedited and formatted. The final version may differ from this version. of promoter activity. The NFY-6 mutation in the putative NF-Y site reduced promoter activity slightly, with a 50% reduction in MCF-7 and a 33% reduction in HepG2. Alteration of a putative AP-1 transcription factor binding site ( Figure 5 ) caused no change in measured promoter activity.
No notable effect on promoter activity was observed in the construct with two mutant regions that altered the 5' portion of the 12 nucleotide conserved region and changed both elements of the 13 nucleotide duplicated segment, Dup1-R7+Dup2-L6 ( Figure 5 ).
The two different segments of the NATb promoter in which mutations showed large effects on relative promoter activity were tested by EMSA to investigate the nature and specificity of protein binding. The oligonucleotide 165L26 containing the putative NATb Sp1 site was shifted by MCF-7 nuclear extract with a shift pattern closely related to the shift pattern seen with a consensus Sp1 recognition site oligonucleotide ( Figure 7A ). The 165L26 shift was also effectively competed by addition of an excess of the consensus Sp1 oligonucleotide ( Figure   7A ). Figure 7B shows that an anti-Sp1 antibody caused a supershift of the 165L26 complex as high-level expression of the NAT2 promoter is limited to liver, colon and small intestine with up to 1000-fold differences in expression between the highest and lowest expressing tissues (Husain et al., 2007) . The alternative NAT1 promoter, NATa, is most highly expressed in a small number of tissues, including kidney, liver, lung, and trachea (Barker et al., 2006) . Thus, the measurements reported here support the view that expression of NAT1 in diverse tissues is primarily due to transcription of NATb. Future investigations monitoring the relative functionality of the alternative promoters will be facilitated by use of the NATb-specific TaqMan assay utilized here together with the previously described NATa-specific TaqMan assay (Barker et al., 2006) which differs only in the sequence of the forward primer. promoter construct eliminates an additional 173 bp from the 5' end of the pGL-257 minimal promoter described previously (Butcher et al., 2005) . Two important functional sites were localized in this minimal region by further deletion and mutation analyses. The presence of a functional Sp1 site was strongly implicated by a conserved alignment with an Sp1 site previously described for the mouse Nat2 promoter (Boukouvala et al., 2003) 
